RedHill Biopharma (NASDAQ:RDHL) is positioning its proprietary oral drug, RHB-102 (Bekinda), as a critical solution to the "discontinuation crisis" facing the blockbuster weight-loss drug market.
Gyre Therapeutics (NASDAQ:GYRE) is moving toward a landmark commercial entry in China after securing alignment with the Center for Drug Evaluation (CDE) on a conditional approval pathway for its lead anti-fibrotic candidate, Hydronidone (F351).
GH Research (NASDAQ:GHRS) shares surged in early trading Monday after the U.S. Food and Drug Administration lifted a long-standing clinical hold on its Investigational New Drug (IND) application for GH001.
Argenx SE (NASDAQ:ARGX) announced a significant leadership transition on Monday, appointing Chief Operating Officer Karen Massey as its new Chief Executive Officer and Executive Director, effective immediately.
HUTCHMED (NASDAQ:HCM) announced today that it has initiated the Phase III stage of its ongoing Phase II/III trial evaluating the combination of surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine (S+C+AG) as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (PDAC) in China.
Mesoblast (NASDAQ:MESO) has implemented a sweeping reorganization of its Board of Directors, effective January 1, 2026, signaling a definitive shift from a research-heavy biotech to a revenue-driven commercial entity.
The leadership transition follows the company's most transformational period, highlighted by the December 2024 FDA approval and subsequent 2025 launch of Ryoncil (remestemcel-L).
Evotec SE (NASDAQ: EVO) announced on January 2, 2026, the appointment of Dr. Sarah Fakih as Executive Vice President, Head of Global Communications and Investor Relations.
In this newly created strategic role, Dr. Fakih will lead an integrated function designed to synchronize Evotec’s corporate messaging with its capital markets strategy.
FibroBiologics (NASDAQ:FBLG) took a decisive step toward clinical-stage operations on Wednesday, filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration to begin Phase 1/2 trials for its lead psoriasis candidate, CYPS317.
Corcept Therapeutics (NASDAQ:CORT) shares plunged Wednesday after the U.S. Food and Drug Administration (FDA) rejected its New Drug Application (NDA) for relacorilant, a treatment for hypertension caused by excessive cortisol levels.
Axsome Therapeutics (NASDAQ:AXSM) shares edged higher Wednesday after the U.S. Food and Drug Administration (FDA) granted Priority Review to its supplemental New Drug Application (sNDA) for AXS-05, a treatment targeting the pervasive and distressing agitation associated with Alzheimer’s disease.
Axsome Therapeutics (NASDAQ:AXSM) is poised to file for U.S. regulatory approval of its narcolepsy treatment, AXS-12, following a successful pre-New Drug Application (NDA) meeting with the Food and Drug Administration.
MetLife Investment Management (MIM), the institutional asset management arm of MetLife (NYSE:MET), completed its acquisition of PineBridge Investments on Tuesday, creating a combined investment powerhouse with approximately $734.7 billion in assets under management.
